Survival Factors in Colorectal Cancer with Immune Checkpoint Inhibitors
A new study of 18,932 metastatic colorectal cancer patients reveals that microsatellite instability, albumin levels, and antibiotic use significantly impact survival rates when treated with immune checkpoint inhibitors, offering insights for personalised treatment.